The Remarkable Journey of Weight Loss Drug Ozempic: Pioneering Scientists Share their Insights

The winding, fitful path to weight loss drug Ozempic has been marked by remarkable breakthroughs and innovative discoveries in the field of biomedical science.
Pioneering Research
Joel Habener, a prominent figure at Massachusetts General Hospital, delved into the intricacies of the pancreatic hormone glucagon, renowned for its ability to increase blood sugar levels in stark contrast to the effects of insulin. On the other hand, Svetlana Mojsov, a distinguished chemist and research associate professor at The Rockefeller University, made significant contributions that laid the groundwork for the development of the potent GLP-1 drugs we have today.
Decades of Dedication
Over the course of half a century, relentless dedication and unwavering commitment to scientific advancement propelled these visionary scientists towards groundbreaking discoveries in the realm of weight loss medications. Their seminal work has paved the way for revolutionary drugs such as Ozempic, which have reshaped the landscape of obesity treatment.
Honoring Excellence
Joel Habener and Svetlana Mojsov have been awarded the prestigious Lasker Award in recognition of their pivotal roles in advancing the field of biomedical research. In a candid conversation with AFP, they reflected on the challenges they faced and the pivotal moments that defined their scientific journey. From humble beginnings to global recognition, their tireless efforts have left an indelible mark on the world of medicine. The journey towards the development of Ozempic serves as a testament to the power of perseverance and innovation in driving scientific progress. Originally published on doc.afp.com, part of the BLOX Digital Content Exchange.